Levetiracetam in Central Pain in Multiple Sclerosis(MS)
Double-blind, Randomised,Placebo-controlled Trial of Levetiracetam in Central Pain in Multiple Sclerosis
What it found
We found no results in the registry or in papers.
This trial finished 17 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Levetiracetam
Synaptic vesicle glycoprotein 2A modulator|Voltage-gated N-type calcium channel alpha-1B subunit blocker
What it measured
Main measures
Pain relief rated on a 0 to 10 point numeric rating scale (median value for last treatment week of each period)
Weekly
Pain
Other measures (9)
Pain rated on a 0 to 10 point numeric rating scale
Daily
PainPain subtypes rated on the same scale.
Daily
PainBrush-evoked pain
Baseline and end of each treatment period
PainPin-prick-evoked pain
Daily
PainCold-evoked pain
Daily
PainHealth related quality of life (SF36)
Baseline and end of each treatment period
Quality of life (reported by participants)Pain related sleep disturbance
Daily
PainMood and sleepUse of escape medication
Daily
Muscle spasms as measured on 2 different scales
Baseline and end of each treatment period
Spasticity
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
* ms diagnosis verified * age > 18 years * central pain symptoms for more than 3 months * central pain diagnosis confirmed by neurological examination * adequate anticonceptive treatment for women with child bearing potential * informed consent * baseline pain of more than 4 on numeric rating scale
Exclusion criteria
* other cause of pain * previous allergic reaction towards levetiracetam * known adverse drug reaction on levetiracetam * pregnancy * severe disease * inability to follow study protocol * treatment with antidepressants, other anticonvulsants or opioids
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Multiple sclerosis is often associated with pain. There is no standard treatment of this type of pain. Levetiracetam is a new anticonvulsant and it is the hypothesis that it could relieve central pain in multiple sclerosis. This is a randomised, double-blind, placebo-controlled, cross-over trial on the effect of levetiracetam 3000 mg daily on pain in multiple sclerosis.
Papers
Loading reviews and guidelines…
Related trials
- Cannabis (THC vs. CBD) in Multiple Sclerosis
Phase 2 · Recruiting
Still running
- ANTIBIOBONTA - Assessment of the interest of a peri-operative antibiot
Phase 3 · Not yet recruiting
Still running
- A study to asses the effects of Nabiximols on spasticity associated wi
Phase 3 · Completed
No results found
- Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Me
Phase 3 · Stopped early
Stopped
- Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinica
Phase 3 · Completed
Missed its main goal
- Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Ther
Phase 3 · Stopped early
Stopped
History
Started
Jan 2007
Main results due
Jan 2009
Finished
Jan 2009